< Back to previous page
Researcher
Elisa Claeys
- Disciplines:Morphological sciences, Oncology
Affiliations
- Laboratory for RNA Cancer Biology (Division)
Member
From6 Jan 2020 → 5 Jan 2021 - Laboratory of Virology and Chemotherapy (Rega Institute) (Division)
Member
From1 Oct 2014 → 5 Jan 2020
Projects
1 - 1 of 1
- Immunosuppressive effects of a CD4 receptor down-modulator: in vitro study of the signal peptide-dependent ER translocation inhibitor cyclotriazadisulfonamide (CADA)From1 Oct 2014 → 26 Sep 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
Publications
1 - 6 of 6
- Small Molecule Cyclotriazadisulfonamide Abrogates the Upregulation of the Human Receptors CD4 and 4-1BB and Suppresses In Vitro Activation and Proliferation of T Lymphocytes(2021)
Authors: Elisa Claeys, Eva Pauwels, Stephanie Humblet-Baron, Dominique Schols, Mark Waer, Ben Sprangers, Kurt Vermeire
- Syntheses and anti-HIV and human cluster of differentiation 4 (CD4) down-modulating potencies of pyridine-fused cyclotriazadisulfonamide (CADA) compounds(2020)
Authors: Elisa Claeys, Kurt Vermeire
- Immunosuppressive drugs in organ transplantation to prevent allograft rejection: Mode of action and side effects(2019)
Authors: Elisa Claeys, Kurt Vermeire
Pages: 14 - 21 - Immunosuppressive effects of a CD4 receptor down-modulator: in vitro study of the signal peptide-dependent ER translocation inhibitor cyclotriazadisulfonamide (CADA)(2019)
Authors: Elisa Claeys, Kurt Vermeire, Dominique Schols, Mark Waer
- The CD4 Receptor: An Indispensable Protein in T Cell Activation and A Promising Target for Immunosuppression(2019)
Authors: Elisa Claeys, Kurt Vermeire
Pages: 133 - 150 - A proteomic survey indicates sortilin as a secondary substrate of the ER translocation inhibitor cyclotriazadisulfonamide (CADA)(2017)
Authors: Victor Van Puyenbroeck, Elisa Claeys, Dominique Schols, Kurt Vermeire
Pages: 157 - 167